NASDAQ:NMTR 9 Meters Biopharma (NMTR) Stock Forecast, Price & News $0.75 +0.04 (+5.63%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$0.70▼$0.7850-Day Range$0.66▼$1.4052-Week Range$0.58▼$13.20Volume87,997 shsAverage Volume95,329 shsMarket Capitalization$10.76 millionP/E RatioN/ADividend YieldN/APrice Target$20.85 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media 9 Meters Biopharma MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside5,790.0% Upside$44.18 Price TargetShort InterestBearish3.68% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.58Based on 4 Articles This WeekInsider TradingSelling Shares$11,011 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.89) to ($4.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.52 out of 5 starsMedical Sector883rd out of 981 stocksPharmaceutical Preparations Industry420th out of 461 stocks 3.2 Analyst's Opinion Consensus Rating9 Meters Biopharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $44.18, 9 Meters Biopharma has a forecasted upside of 5,790.0% from its current price of $0.75.Amount of Analyst Coverage9 Meters Biopharma has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.68% of the float of 9 Meters Biopharma has been sold short.Short Interest Ratio / Days to Cover9 Meters Biopharma has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in 9 Meters Biopharma has recently increased by 8.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yield9 Meters Biopharma does not currently pay a dividend.Dividend Growth9 Meters Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NMTR. Previous Next 1.3 News and Social Media Coverage News Sentiment9 Meters Biopharma has a news sentiment score of -0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for 9 Meters Biopharma this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for NMTR on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat Follows4 people have added 9 Meters Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 9 Meters Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,011.00 in company stock.Percentage Held by InsidersOnly 2.40% of the stock of 9 Meters Biopharma is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for 9 Meters Biopharma are expected to decrease in the coming year, from ($2.89) to ($4.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 9 Meters Biopharma is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 9 Meters Biopharma is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio9 Meters Biopharma has a P/B Ratio of 3.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About 9 Meters Biopharma (NASDAQ:NMTR) Stock9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.Read More Receive NMTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 9 Meters Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address NMTR Stock News HeadlinesJune 2, 2023 | americanbankingnews.com9 Meters Biopharma, Inc. to Post Q2 2023 Earnings of ($1.06) Per Share, William Blair Forecasts (NASDAQ:NMTR)May 30, 2023 | bizjournals.comTemperato resigns as CEO of Raleigh drugmakerJune 8, 2023 | UNKNOWN (Ad)This NASDAQ Stock Is The Amazon Of Medical SupplyThis Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More NowMay 30, 2023 | finance.yahoo.com9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel SyndromeMay 29, 2023 | americanbankingnews.comReviewing 9 Meters Biopharma (NASDAQ:NMTR) & Iterum Therapeutics (NASDAQ:ITRM)May 28, 2023 | fool.com9 Meters Biopharma (NASDAQ: NMTR)May 27, 2023 | americanbankingnews.com9 Meters Biopharma (NASDAQ:NMTR) Stock Rating Lowered by Brookline Capital ManagementMay 27, 2023 | americanbankingnews.com9 Meters Biopharma (NASDAQ:NMTR) Lowered to Hold at Brookline Capital ManagementJune 8, 2023 | UNKNOWN (Ad)This NASDAQ Stock Is The Amazon Of Medical SupplyThis Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More NowMay 25, 2023 | uk.finance.yahoo.comNMTR - 9 Meters Biopharma, Inc.May 24, 2023 | americanbankingnews.com9 Meters Biopharma, Inc. (NASDAQ:NMTR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 22, 2023 | americanbankingnews.comCitigroup Trims 9 Meters Biopharma (NASDAQ:NMTR) Target Price to $1.70May 20, 2023 | americanbankingnews.comWilliam Blair Weighs in on 9 Meters Biopharma, Inc.'s Q2 2023 Earnings (NASDAQ:NMTR)May 19, 2023 | msn.comCitigroup Maintains 9 Meters Biopharma (NMTR) Neutral RecommendationMay 15, 2023 | finance.yahoo.com9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023May 4, 2023 | americanbankingnews.comAnalysts Set 9 Meters Biopharma, Inc. (NASDAQ:NMTR) PT at $45.57April 24, 2023 | americanbankingnews.comInsider Selling: 9 Meters Biopharma, Inc. (NASDAQ:NMTR) CFO Sells 9,100 Shares of StockApril 9, 2023 | americanbankingnews.comBrokerages Set 9 Meters Biopharma, Inc. (NASDAQ:NMTR) PT at $45.57April 5, 2023 | finance.yahoo.com9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for ObesityApril 2, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for 9 Meters Biopharma, Inc. Reduced by William Blair (NASDAQ:NMTR)March 31, 2023 | americanbankingnews.comBrookline Capital Management Comments on 9 Meters Biopharma, Inc.'s Q1 2023 Earnings (NASDAQ:NMTR)March 31, 2023 | americanbankingnews.comOppenheimer Comments on 9 Meters Biopharma, Inc.'s Q1 2023 Earnings (NASDAQ:NMTR)March 31, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for 9 Meters Biopharma, Inc. Lifted by Analyst (NASDAQ:NMTR)March 31, 2023 | americanbankingnews.com9 Meters Biopharma, Inc. Forecasted to Post Q1 2023 Earnings of ($0.73) Per Share (NASDAQ:NMTR)March 30, 2023 | bizjournals.comWhy this Raleigh pharma just cut half its workforceMarch 28, 2023 | finance.yahoo.com9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022March 28, 2023 | americanbankingnews.comBrookline Capital Management Comments on 9 Meters Biopharma, Inc.'s FY2022 Earnings (NASDAQ:NMTR)See More Headlines NMTR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NMTR Company Calendar Last Earnings11/15/2021Today6/07/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NMTR CUSIPN/A CIK1551986 Webwww.9meters.com Phone(919) 275-1933FaxN/AEmployees21Year FoundedN/APrice Target and Rating Average Stock Price Forecast$44.18 High Stock Price Forecast$100.00 Low Stock Price Forecast$1.70 Forecasted Upside/Downside+2,680.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-584.97% Return on Assets-159.45% Debt Debt-to-Equity RatioN/A Current Ratio0.59 Quick Ratio0.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book3.95Miscellaneous Outstanding Shares14,340,000Free Float13,992,000Market Cap$10.76 million OptionableOptionable Beta1.36 Key ExecutivesJohn TemperatoPresident, Chief Executive Officer & DirectorSireesh AppajosyulaSVP-Corporate Development & OperationsBethany L. SensenigChief Financial OfficerPatrick H. GriffinChief Medical OfficerNir BarakSenior Vice President-Scientific AffairsKey CompetitorsPulmatrixNASDAQ:PULMCan-Fite BioPharmaNYSE:CANFBright Minds BiosciencesNASDAQ:DRUGCyclerion TherapeuticsNASDAQ:CYCNAptorum GroupNASDAQ:APMView All CompetitorsInsiders & InstitutionsSabby Management LLCBought 1,103,102 shares on 5/16/2023Ownership: 7.698%Susquehanna International Group LLPSold 1,000 shares on 5/16/2023Ownership: 0.000%CIBC Asset Management IncBought 32,722 shares on 5/12/2023Ownership: 0.228%HRT Financial LPSold 24,281 shares on 5/12/2023Ownership: 0.127%Bethany SensenigSold 9,100 sharesTotal: $11,011.00 ($1.21/share)View All Insider TransactionsView All Institutional Transactions NMTR Stock - Frequently Asked Questions Should I buy or sell 9 Meters Biopharma stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 9 Meters Biopharma in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NMTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NMTR, but not buy additional shares or sell existing shares. View NMTR analyst ratings or view top-rated stocks. What is 9 Meters Biopharma's stock price forecast for 2023? 6 Wall Street analysts have issued 12-month price targets for 9 Meters Biopharma's shares. Their NMTR share price forecasts range from $1.70 to $100.00. On average, they predict the company's stock price to reach $44.18 in the next twelve months. This suggests a possible upside of 5,790.0% from the stock's current price. View analysts price targets for NMTR or view top-rated stocks among Wall Street analysts. How have NMTR shares performed in 2023? 9 Meters Biopharma's stock was trading at $1.26 at the beginning of 2023. Since then, NMTR stock has decreased by 40.5% and is now trading at $0.75. View the best growth stocks for 2023 here. When is 9 Meters Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our NMTR earnings forecast. How were 9 Meters Biopharma's earnings last quarter? 9 Meters Biopharma, Inc. (NASDAQ:NMTR) released its quarterly earnings results on Monday, November, 15th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $0.26. When did 9 Meters Biopharma's stock split? 9 Meters Biopharma's stock reverse split on Tuesday, October 18th 2022. The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of 9 Meters Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other 9 Meters Biopharma investors own include Acasti Pharma (ACST), Miragen Therapeutics (MGEN), Bionano Genomics (BNGO), Evofem Biosciences (EVFM), Outlook Therapeutics (OTLK), Tonix Pharmaceuticals (TNXP), Alibaba Group (BABA), Cellectar Biosciences (CLRB), Pfizer (PFE) and Soleno Therapeutics (SLNO). What is 9 Meters Biopharma's stock symbol? 9 Meters Biopharma trades on the NASDAQ under the ticker symbol "NMTR." Who are 9 Meters Biopharma's major shareholders? 9 Meters Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Sabby Management LLC (7.70%), CIBC Asset Management Inc (0.23%), Susquehanna International Group LLP (0.00%) and HRT Financial LP (0.13%). Insiders that own company stock include Bethany Sensenig, Edward J Sitar, Israel Gp Ltd Orbimed, John Temperato, Mark A Sirgo and Michael T Constantino. View institutional ownership trends. How do I buy shares of 9 Meters Biopharma? Shares of NMTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is 9 Meters Biopharma's stock price today? One share of NMTR stock can currently be purchased for approximately $0.75. How much money does 9 Meters Biopharma make? 9 Meters Biopharma (NASDAQ:NMTR) has a market capitalization of $10.76 million. The company earns $-43,770,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis. How can I contact 9 Meters Biopharma? 9 Meters Biopharma's mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The official website for the company is www.9meters.com. The company can be reached via phone at (919) 275-1933 or via email at investor-relations@9meters.com. This page (NASDAQ:NMTR) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.